Best Practices for Claim Construction: summarizing current law post Nautilus, Inc. v. Biosig Instruments, Inc. and Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc
When:
Location:
Hotel Hilton (Mumbai) and Stellar Gymkhana Greater Noida (Delhi), India
Share this page:
Best Practices for Claim Construction: summarizing current law post Nautilus, Inc. v. Biosig Instruments, Inc. and Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc", Discussion on determining subject matter patentability of method patents in life sciences domain based on Federal Circuit’s decision in Rapid Litigation Management Ltd. v. CellzDirect, Inc. and prior 101 jurisprudence post-Myriad and Review and impact of Mayo, Myriad, and Ariosa decisions on recent USPTO and Federal Circuit decisions addressing 101 rejections for biotech patents.
This website does not track your personal or demographic information, only anonymous usage statistics. To ensure that you are not tracked, we have blocked all embedded content from third party sources like YouTube and SlideShare. Click "Accept Cookies" to enable third-party content. To learn more about our cookie policy, click here.